FDA faces congressional probes and more transparency and organizational changes

被引：0
|
作者：
Wechsler, Jill
机构：
来源：
FORMULARY | 2011年 / 46卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：66 / 67
页数：2
相关论文
共 8 条
  • [1] Clinical Trial Transparency: The FDA Should and Can Do More
    Kapczynski, Amy
    Kim, Jeanie
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 33 - 38
  • [2] FDA proposes changes in drug information regulation to prevent congressional action
    Wechsler, J
    FORMULARY, 1996, 31 (07) : 623 - 624
  • [3] Transparency Initiative to provide more information on FDA regulation and drug development
    Wechsler, Jill
    FORMULARY, 2010, 45 (07) : 232 - 233
  • [4] Law Watch: More on Organizational Changes
    Kathrin S. Mautino
    Journal of Immigrant Health, 2003, 5 (4): : 141 - 142
  • [5] The Politics of Open Government Data: Understanding Organizational Responses to Pressure for More Transparency
    Ruijer, Erna
    Detienne, Francoise
    Baker, Michael
    Groff, Jonathan
    Meijer, Albert J.
    AMERICAN REVIEW OF PUBLIC ADMINISTRATION, 2020, 50 (03): : 260 - 274
  • [6] The More Transparent, the Better? Effects of Transparency Regime Changes on Large/Actively Traded Stocks on the Korea Exchange
    Khil, Jaeuk
    Park, Young S.
    Shin, Jhinyoung
    EMERGING MARKETS FINANCE AND TRADE, 2012, 48 : 133 - 152
  • [7] How firms undertake organizational changes to shift to more-exploratory strategies: A process perspective
    Vedel, Jane Bjorn
    Kokshagina, Olga
    RESEARCH POLICY, 2021, 50 (01)
  • [8] The More-or-Less Morphing Face Illusion Revisited: Perceiving Natural Transient Changes in Faces Despite Fast Saccades
    Utz, Sandra
    Carbon, Claus-Christian
    I-PERCEPTION, 2020, 11 (04):
1